| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5582016 | Clinical Lymphoma Myeloma and Leukemia | 2017 | 31 Pages |
Abstract
A variety of assessment methods beyond palpable spleen length that are easily accessible in the community setting might be useful in evaluating the clinical benefit of ruxolitinib over time in patients with MF.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Carole B. Miller, Rami S. Komrokji, Ruben A. Mesa, William Sun, Michael Montgomery, Srdan Verstovsek,